MCID: HPT007
MIFTS: 53

Hepatitis E

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis E

MalaCards integrated aliases for Hepatitis E:

Name: Hepatitis E 12 75 53 55 44 15 17 72

Classifications:



External Ids:

Disease Ontology 12 DOID:4411
MeSH 44 D016751
UMLS 72 C0085293

Summaries for Hepatitis E

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis E virus, which is transmitted by ingestion of contaminated food. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom dark urine, has symptom joint pain, and has symptom jaundice.

MalaCards based summary : Hepatitis E is related to viral hepatitis and acute liver failure, and has symptoms including fever, vomiting and fatigue. An important gene associated with Hepatitis E is CD40LG (CD40 Ligand), and among its related pathways/superpathways are HIV Life Cycle and Development Angiotensin activation of ERK. The drugs Ribavirin and interferons have been mentioned in the context of this disorder. Affiliated tissues include liver, liver and kidney, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Wikipedia : 75 Hepatitis E is inflammation of the liver caused by infection with the hepatitis E virus (HEV). One of... more...

Related Diseases for Hepatitis E

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E

Diseases related to Hepatitis E via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 312)
# Related Disease Score Top Affiliating Genes
1 viral hepatitis 31.5 GPT F2 ALB
2 acute liver failure 31.2 GPT F2 ALB
3 hepatitis a 31.0 IFNG GPT F2 ALB
4 hepatic coma 30.7 GPT F2 ALB
5 hepatitis d 30.6 GPT F2
6 hepatic encephalopathy 30.6 GPT F2 ALB
7 non-a-e hepatitis 30.4 F2 ALB
8 liver cirrhosis 30.4 GPT F2 ALB
9 hepatitis c 30.3 TLR3 IFNG GPT
10 bilirubin metabolic disorder 30.2 GPT F2 ALB
11 cholangitis 30.2 GPT F2 ALB
12 hepatitis c virus 30.1 IFNG GRB2 GPT
13 hepatitis b 30.1 IFNG GPT F2 ALB
14 cholecystitis 30.0 GPT F2 ALB
15 typhoid fever 29.9 IFNG F2 ALB
16 alcoholic hepatitis 29.8 GPT F2 ALB
17 portal hypertension 29.8 GPT F2 ALB
18 infantile liver failure syndrome 1 29.7 GPT F2 ALB
19 choledocholithiasis 29.6 GPT F2 ALB
20 hepatorenal syndrome 29.6 F2 ALB
21 pure red-cell aplasia 29.4 RPS17 ALB
22 schistosomiasis 29.3 IFNG F2 CD40LG ALB
23 viral infectious disease 29.2 TLR3 IFNG GPT CD40LG
24 human immunodeficiency virus type 1 29.1 TSG101 TLR3 IFNG FYN
25 pneumocystosis 28.8 CD40LG ALB
26 hepatitis 11.1
27 liver disease 10.6
28 hepatoportal sclerosis 10.5 GPT F2
29 guillain-barre syndrome 10.4
30 antipyrine metabolism 10.4 F2 ALB
31 epstein-barr virus hepatitis 10.4 F2 ALB
32 hypertensive nephropathy 10.4 AMBP ALB
33 amyotrophic neuralgia 10.4
34 abdominal tuberculosis 10.4 F2 ALB
35 autoimmune hepatitis 10.3
36 splenomegaly 10.3
37 cholestasis 10.3
38 splenic disease 10.3 F2 ALB
39 chronic graft versus host disease 10.3 IFNG ALB
40 variola major 10.3 TLR3 IFNG
41 ascending cholangitis 10.3 F2 ALB
42 esophageal varix 10.3 F2 ALB
43 encephalopathy 10.2
44 tuberculous peritonitis 10.2 IFNG ALB
45 chronic inflammatory demyelinating polyradiculoneuropathy 10.2 IFNG ALB
46 sporotrichosis 10.2 IFNG CD40LG
47 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
48 acute pancreatitis 10.2
49 african tick-bite fever 10.2 IFNG CD40LG
50 compartment syndrome 10.2 F2 ALB

Graphical network of the top 20 diseases related to Hepatitis E:



Diseases related to Hepatitis E

Symptoms & Phenotypes for Hepatitis E

Symptoms:

12
  • fever
  • vomiting
  • fatigue
  • abdominal pain
  • jaundice
  • nausea
  • dark urine
  • loss of appetite
  • joint pain
  • clay-colored bowel movements

MGI Mouse Phenotypes related to Hepatitis E:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.97 ALB AMBP CD40LG FGB FYN GRB2
2 homeostasis/metabolism MP:0005376 9.86 ALB CD40LG F2 FYN GRB2 IFNG
3 neoplasm MP:0002006 9.55 ALB GRB2 IFNG TLR3 TSG101
4 renal/urinary system MP:0005367 9.43 ALB CD40LG FYN GRB2 IFNG TSG101
5 reproductive system MP:0005389 9.23 AMBP CD40LG F2 FGB FYN GRB2

Drugs & Therapeutics for Hepatitis E

Drugs for Hepatitis E (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ribavirin Approved Phase 4 36791-04-5 37542
2 interferons Phase 4
3 Interferon-alpha Phase 4
4 Anti-Infective Agents Phase 4
5 Antiviral Agents Phase 4
6 Antimetabolites Phase 4
7
Aluminum hydroxide Approved, Investigational Phase 3 21645-51-2
8
Aluminum sulfate Approved Phase 3 10043-01-3
9
Milk thistle Approved, Experimental, Investigational Phase 2, Phase 3 65666-07-1
10
Nicotinamide Approved, Investigational Phase 2, Phase 3 98-92-0 936
11
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
12
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 2, Phase 3 59-43-8, 70-16-6 1130
13
Niacin Approved, Investigational, Nutraceutical Phase 2, Phase 3 59-67-6 938
14
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 2, Phase 3 83-88-5 493570
15 Sunflower Phase 3
16 Trace Elements Phase 2, Phase 3
17 Micronutrients Phase 2, Phase 3
18 Antioxidants Phase 2, Phase 3
19 silymarin Phase 2, Phase 3
20 Vitamins Phase 2, Phase 3
21 Protective Agents Phase 2, Phase 3
22 Vitamin B Complex Phase 2, Phase 3
23 Vitamin B9 Phase 2, Phase 3
24 Folate Phase 2, Phase 3
25 Vitamin B3 Phase 2, Phase 3
26 Nicotinic Acids Phase 2, Phase 3
27 Vitamin B2 Phase 2, Phase 3
28 Thiamin Phase 2, Phase 3
29 Nutrients Phase 2, Phase 3
30
Sofosbuvir Approved Phase 2 1190307-88-0 45375808
31
Phenoxyethanol Approved Phase 2 122-99-6 31236
32
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
33
Peginterferon alfa-2a Approved, Investigational Phase 2 198153-51-4 5360545
34
Entecavir Approved, Investigational Phase 2 142217-69-4 153941
35 Dexelvucitabine Investigational Phase 2 134379-77-4
36
Tenofovir Experimental, Investigational Phase 2 147127-20-6 464205
37 Nucleic Acid Synthesis Inhibitors Phase 2
38 Reverse Transcriptase Inhibitors Phase 2
39 Anti-HIV Agents Phase 2
40 Anti-Retroviral Agents Phase 2
41 Pharmaceutical Solutions Phase 1
42
Permethrin Approved, Investigational 52645-53-1 40326
43
Resveratrol Approved, Experimental, Investigational 501-36-0 445154
44 Antibodies
45 Immunoglobulins
46 Analgesics
47 Analgesics, Non-Narcotic
48 Antineoplastic Agents, Phytogenic
49 Peripheral Nervous System Agents
50 Anti-Inflammatory Agents, Non-Steroidal

Interventional clinical trials:

(show all 40)
# Name Status NCT ID Phase Drugs
1 Evaluation of Safety and Immunogenicity of Recombinant (E. Coli) Hepatitis E Vaccine(Hecolin®) in Seniors Aged Over 65 Years Completed NCT02189603 Phase 4
2 Safety and Immunogenicity Study of the Recombinant Hepatitis E Vaccine(Escherichia Coli) in Healthy Volunteers Aged Over 65 Years Completed NCT02417597 Phase 4
3 A Study on Immunogenicity of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® Using Accelerated Vaccination Schedule in Adults (Aged Over 18 Years) Completed NCT03168412 Phase 4
4 An Open, Pared Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® in the Chronic Hepatitis B Patients on the Clinical Stability .( Aged 30 Years or Over) Completed NCT02964910 Phase 4
5 Safety and Immunogenicity Study of the Recombinant Hepatitis E Vaccine(Escherichia Coli) Coadministration With Recombinant Hepatitis B Vaccine Completed NCT02584543 Phase 4
6 A Study of Peg-interferon Treatment for Nucleos(t)Ide Analogues Suppressed Chronic Hepatitis B Patients With Low Level Hepatitis Surface Antigen Recruiting NCT04035837 Phase 4 pegylated interferon-alfa
7 An Effectiveness Trial (Phase IV) to Evaluate Protection of Pregnant Women by Hepatitis E Virus (HEV) Vaccine in Bangladesh and Risk Factors for Severe HEV Infection. Active, not recruiting NCT02759991 Phase 4 Hecolin;Hepa-B
8 Randomized Study of Two Treatment Strategies With Ribavirin for Chronic Hepatitis E and Severe Acute Forms Terminated NCT02558114 Phase 4 Ribavirin
9 An Randomized, Double-blinded Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® to Evaluate Lot-to-lot Consistency Withdrawn NCT03365921 Phase 4
10 A Phase 3, Randomized, Double-blind, Placebo (Hepatitis B Vaccine) Controlled Clinical Trial of Recombinant (E. Coli) Hepatitis E Vaccine Unknown status NCT01014845 Phase 3
11 Field Trial of Maternal Influenza Immunization in Asia Unknown status NCT01034254 Phase 3
12 A Phase III Multicenter, Randomized, Double-Blind, Placebo(Hepatitis E Vaccine)Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant(E.Coli)Human Papillomavirus Bivalent Vaccine in Healthy Women Active, not recruiting NCT01735006 Phase 3
13 Randomized Trial to Evaluate Mirasol Whole Blood Pathogen Reduction Technology System to Reduce Malaria and Emerging Transfusion Transmitted Infections Not yet recruiting NCT03737669 Phase 3
14 A Multicentre, Double-blind, Randomized, Placebo-controlled, Phase II/III Study to Evaluate the Safety and Efficacy of 280 mg and 420 mg Silymarin TID (Legalon® Capsules) Administered for Four Weeks in Subjects With Acute Viral Hepatitis With a Four Week Follow-up Period Terminated NCT00755950 Phase 2, Phase 3
15 A Double Blind Placebo Controlled Randomized Trial of Ribavirin in Patients With Acute on Chronic Liver Failure Due to Hepatitis E Virus Unknown status NCT01698723 Phase 2 Ribavirin;Placebo
16 HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE) Completed NCT03282474 Phase 2 Sofosbuvir
17 A Phase II, Prospective, Randomized, Double-blind, Placebo Controlled, Field Efficacy Trial of a Candidate Hepatitis E Vaccine in Nepal. Completed NCT00287469 Phase 2
18 A Double-Blind, Randomized Trial of Antiviral Activity and Safety of 12 Weeks Oral Treatment With ACH-126,443 (Beta-L-Fd4C) in Treatment-Naive HBV-Infected Adults Completed NCT00034359 Phase 2 ACH-126, 443 (beta-L-Fd4C);Lamivudine;Placebo
19 Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients With Chronic Hepatitis B Virus Infection Who Are HBeAg-positive Completed NCT01204762 Phase 2 pegIFN;pegIFNα-2a;PegIFN lambda;Entecavir
20 A PhaseⅡ Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Immunogenicity of the Recombinant (E.Coli) Human Papillomavirus Type 6/11 Bivalent Vaccine in Healthy Volunteers Aged 18-55 Years Active, not recruiting NCT02710851 Phase 2
21 A Phase 2, Open-label, Randomized, Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic Hepatitis B Virus Active, not recruiting NCT02751996 Phase 2 SB 9200;Placebo;Tenofovir
22 A Phase Ib Single Center, Randomized, Blinding, Parallel-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Hepatitis E Vaccine in Healthy Adults Aged 16 to 65 Years Old in China Completed NCT02603055 Phase 1
23 A Phase 1, Double-Blinded, Placebo Controlled, Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of HEV-239 (Hecolin(R)) in a Healthy US Adult Population Recruiting NCT03827395 Phase 1
24 Hepatitis E Virus Infection in Pediatric Transplantation, a Prevalence Study Unknown status NCT02809885
25 Epidemiological Study of Hepatitis E Virus in Maintenance Hemodialysis Patients Unknown status NCT02645955
26 The Epidemiology of Hepatitis E Virus Infection in Israel and Potential Risk Factors, a Multicenter, Comparative, Cross-sectional Study Unknown status NCT02419625
27 Natural Course of Acute Icteric Viral Hepatitis in Type II Diabetes Mellitus Patients and Non-Diabetic Patients:A Pilot Cohort Study Unknown status NCT00689546
28 Investigation of Endemic and Emerging Diseases in Populations of Homeless Households in Marseille. Unknown status NCT02819128
29 A Prospective Multicenter Study of Acute on Chronic Liver Failure in China Unknown status NCT02457637
30 Seroprevalence of Hepatitis E in HIV Positive Patients in Basque Country in 2016 (VIhVhEpb): a Prospective Cohort Study Completed NCT02847507
31 Hepatitis E in the Organ Transplant Population Completed NCT02190253
32 Host Responses in Kidney-transplant Recipients With Chronic Hepatitis E Virus Infection Completed NCT01090232
33 Role of Cytokines in Hepatitis E Virus Infection During Pregnancy Completed NCT01062321
34 A Point Prevalence Study to Evaluate the Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Who Are Receiving Porcine-Derived Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors Completed NCT01858519
35 The Curative Effect and Security of Interferon Combined Resveratrol on HBeAg Positive Chronic Hepatitis B Patients - a Multi-center, Random, Control, Open Clinical Trial. Completed NCT03546530 Interferon;Interferon+resveratrol
36 The Curative Effect and Security of Entecavir Combined Thymosin or Resveratrol on HBeAg Positive Chronic Hepatitis B Patients - a Multi-center, Random, Control, Open Clinical Trial Completed NCT03509688 entecavir+resveratrol;Entecavir;entecavir+thymosin α1
37 Hepatitis E Infection : Emergence Mechanisms in North-Eastern France of Polymorphic Clinical Forms. Recruiting NCT03524014
38 Observational Study on Seroprevalence of Hepatitis E Infection in Healthy Blood Donors in the Canton Ticino Recruiting NCT03601221
39 A Prospective Multi-center Validating Cohort for ACLF Diagnosis and Prognosis From Ch-CANONIC Study Recruiting NCT03641872
40 Hepatitis E Virus Infection Among Patients With Acute Non-A, Non-B, Non-C Hepatitis in Al-Rajhy University Hospital for Liver Not yet recruiting NCT03488589

Search NIH Clinical Center for Hepatitis E

Cochrane evidence based reviews: hepatitis e

Genetic Tests for Hepatitis E

Anatomical Context for Hepatitis E

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis E:

19
Liver

MalaCards organs/tissues related to Hepatitis E:

41
Liver, Kidney, Testes, T Cells, Heart, B Cells, Lung

Publications for Hepatitis E

Articles related to Hepatitis E:

(show top 50) (show all 4821)
# Title Authors PMID Year
1
Value of hepatitis E virus detection by cell culture compared with nested PCR and serological studies by IgM and IgG. 9 38
19374667 2009
2
A novel mycovirus that is related to the human pathogen hepatitis E virus and rubi-like viruses. 9 38
19073734 2009
3
Double-antigen enzyme-linked immunosorbent assay for detection of hepatitis E virus-specific antibodies in human or swine sera. 9 38
18495846 2008
4
Hepatitis E virus coinfection with hepatotropic viruses in Egyptian children. 9 38
18629421 2008
5
Active surveillance for acute viral hepatitis in rural villages in the Nile Delta. 9 38
16447107 2006
6
The 41-amino-acid C-terminal region of the hepatitis E virus ORF3 protein interacts with bikunin, a kunitz-type serine protease inhibitor. 9 38
16140784 2005
7
Simultaneous detection of immunoglobulin A (IgA) and IgM antibodies against hepatitis E virus (HEV) Is highly specific for diagnosis of acute HEV infection. 9 38
15634950 2005
8
Prevalence of hepatitis E virus in Egyptian children presented with minor hepatic disorders. 9 38
17977212 2005
9
Prevalence of antibodies to hepatitis E virus among Japanese blood donors: identification of three blood donors infected with a genotype 3 hepatitis E virus. 9 38
15221899 2004
10
The ORF3 protein of hepatitis E virus interacts with liver-specific alpha1-microglobulin and its precursor alpha1-microglobulin/bikunin precursor (AMBP) and expedites their export from the hepatocyte. 9 38
15037615 2004
11
Molecular and serological characterization of sporadic acute hepatitis E in a Japanese patient infected with a genotype III hepatitis E virus in 1993. 9 38
12560575 2003
12
Clinical and epidemiological relevance of quantitating hepatitis E virus-specific immunoglobulin M. 9 38
12204962 2002
13
Sero-epidemiology of hepatitis E virus (HEV) in urban and rural children of North India. 9 38
11359972 2001
14
Diagnostic value of immunoglobulin G (IgG) and IgM anti-hepatitis E virus (HEV) tests based on HEV RNA in an area where hepatitis E is not endemic. 9 38
11060044 2000
15
[Dynamics of anti-HEV ORF2, ORF3, IgM and IgG in serial sera of patients with hepatitis E and their clinical significance]. 9 38
10923456 1998
16
Role of immune serum globulins in pregnant women during an epidemic of hepatitis E. 9 38
9658374 1998
17
[Diagnosis of hepatitis E virus infection in sporadic acute hepatitis]. 9 38
15619831 1997
18
Acute sporadic hepatitis E virus infection in southern China. 9 38
8550986 1995
19
Changes of pre-S1 and pre-S2 antigens in sera of patients with hepatitis B virus infection. 9 38
2170220 1990
20
Prevalence and identification of arthropod-transmitted viruses in Kassala state, Eastern Sudan. 38
30716013 2019
21
First detection of Hepatitis E virus (Orthohepevirus C) in wild brown rats (Rattus norvegicus) from Great Britain. 38
31033238 2019
22
Quantification and genetic diversity of Hepatitis E virus in wild boar (Sus scrofa) hunted for domestic consumption in Central Italy. 38
31027773 2019
23
Identification and genetic characterization of a porcine hepe-astrovirus (bastrovirus) in the United States. 38
31175435 2019
24
The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study. 38
31108159 2019
25
Prevalence of hepatitis E virus infection in multiple transfused Brazilian patients with thalassemia and sickle cell disease. 38
31066064 2019
26
Evaluation of the VIDAS hepatitis E IgM test in a nonendemic region. 38
31196687 2019
27
Viral load and clinical manifestations of hepatitis E virus genotype 3 infections. 38
31099059 2019
28
Cross-sectional Seroprevalence and Genotype of Hepatitis E Virus in Humans and Swine in a High-density Pig-farming Area in Central China. 38
31264049 2019
29
Are VIDAS® anti-HEV IgM and IgG assays fit for reliable diagnosis of hepatitis E virus infections? Comparison & case story telling. 38
31402757 2019
30
Sofosbuvir Add-on to Ribavirin Treatment for Chronic Hepatitis E Virus Infection in Solid Organ Transplant Recipients Does Not Result in Sustained Virological Response. 38
31404927 2019
31
Occupational swine exposure and Hepatitis E virus, Leptospira, Ascaris suum seropositivity and MRSA colonization in Austrian veterinarians, 2017-2018-A cross-sectional study. 38
31419070 2019
32
Incidence, predictors and prognosis of genotype 4 hepatitis E related liver failure: A tertiary nested case-control study. 38
31436371 2019
33
Hepatitis E infection in a patient with rheumatoid arthritis treated with leflunomide: A case report with emphasis on geoepidemiology. 38
31415347 2019
34
Altered antigenicity and immunogenicity of human papillomavirus virus-like particles in the presence of thimerosal. 38
31154067 2019
35
Human Seroprevalence to 11 Zoonotic Pathogens in the U.S. Arctic, Alaska. 38
30789314 2019
36
HEV seroprevalence in blood donors in Turkey by two commercial total anti-HEV Ab ELISA kits. 38
31403185 2019
37
Genomic and spatial variability of a European common vole hepevirus. 38
31399875 2019
38
Immune dissociation during acute hepatitis E infection. 38
31408707 2019
39
Safe supplies: few infections in UK blood and tissue donors. 38
30689250 2019
40
Enterically Transmitted Non-A, Non-B Hepatitis and the Discovery of Hepatitis E Virus. 38
29735576 2019
41
Changing incidence of reported viral hepatitis in China from 2004 to 2016: an observational study. 38
31427323 2019
42
Screening of novel drugs for inhibiting hepatitis E virus replication. 38
31004661 2019
43
Metagenomic next-generation sequencing aids the diagnosis of viral infections in febrile returning travellers. 38
31398374 2019
44
No evidence of occult hepatitis C or E virus infections in liver-transplant patients with sustained virological response after therapy with direct acting agents. 38
30972874 2019
45
Hepatitis E Virus Replication. 38
31390784 2019
46
Electrical pulse-induced electrochemical biosensor for hepatitis E virus detection. 38
31427581 2019
47
Rat Hepatitis E Virus Linked to Severe Acute Hepatitis in an Immunocompetent Patient. 38
30649379 2019
48
Small Animal Models of Hepatitis E Virus Infection. 38
29735581 2019
49
Cutaneous necrotizing small-vessel vasculitis induced by acute hepatitis E. 38
31428384 2019
50
Convalescent plasma therapy for persistent hepatitis E virus infection. 38
31075322 2019

Variations for Hepatitis E

Expression for Hepatitis E

Search GEO for disease gene expression data for Hepatitis E.

Pathways for Hepatitis E

Pathways related to Hepatitis E according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.59 VPS4A TSG101 TLR3 RPS17 GRB2 FYN
2
Show member pathways
12.48 GRB2 FYN FGB F2 CD40LG
3
Show member pathways
12.26 IFNG GRB2 FYN CD40LG
4
Show member pathways
12.09 IFNG GRB2 FYN F2
5
Show member pathways
11.98 GRB2 FYN F2
6
Show member pathways
11.96 VPS4A TLR3 IFNG
7 11.9 TLR3 IFNG GRB2
8
Show member pathways
11.8 IFNG GRB2 FYN CD40LG
9
Show member pathways
11.78 IFNG GRB2 FYN
10 11.72 IFNG GRB2 FYN
11
Show member pathways
11.32 GRB2 FGB F2
12 10.95 GRB2 FYN
13 10.92 IFNG F2
14 10.84 IFNG GRB2
15 10.71 GRB2 FYN
16 10.57 GRB2 FYN

GO Terms for Hepatitis E

Cellular components related to Hepatitis E according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.76 VPS4A TSG101 GRB2 GPT FGB F2
2 endosome GO:0005768 9.65 VPS4A TSG101 TLR3 GRB2 FYN
3 Flemming body GO:0090543 9.32 VPS4A TSG101
4 blood microparticle GO:0072562 9.26 FGB F2 AMBP ALB
5 extracellular space GO:0005615 9.23 TLR3 IFNG GPT FGB F2 CD40LG

Biological processes related to Hepatitis E according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.78 TSG101 GRB2 FYN AMBP
2 blood coagulation GO:0007596 9.73 FYN FGB F2
3 viral life cycle GO:0019058 9.55 VPS4A TSG101
4 positive regulation of reactive oxygen species metabolic process GO:2000379 9.54 GRB2 F2
5 multivesicular body assembly GO:0036258 9.52 VPS4A TSG101
6 negative regulation of epidermal growth factor receptor signaling pathway GO:0042059 9.51 TSG101 GRB2
7 T cell costimulation GO:0031295 9.5 GRB2 FYN CD40LG
8 positive regulation of protein localization to nucleus GO:1900182 9.49 FYN F2
9 fibrinolysis GO:0042730 9.46 FGB F2
10 viral budding via host ESCRT complex GO:0039702 9.43 VPS4A TSG101
11 ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway GO:0043162 9.4 VPS4A TSG101
12 positive regulation of viral release from host cell GO:1902188 9.37 VPS4A TSG101
13 positive regulation of interleukin-12 production GO:0032735 9.33 TLR3 IFNG CD40LG
14 positive regulation of viral budding via host ESCRT complex GO:1903774 9.26 VPS4A TSG101
15 platelet activation GO:0030168 9.26 FYN FGB F2 CD40LG
16 positive regulation of exosomal secretion GO:1903543 8.8 VPS4A TSG101 IFNG

Molecular functions related to Hepatitis E according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ephrin receptor binding GO:0046875 8.62 GRB2 FYN

Sources for Hepatitis E

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....